ENTRY       D11117                      Drug
NAME        Rovalpituzumab (USAN)
FORMULA     C6416H9894N1698O2028S46
EXACT_MASS  144649.0426
MOL_WEIGHT  144738.3594
SEQUENCE    (Heavy chain)
            QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYGMNWVRQA PGQGLEWMGW INTYTGEPTY
            ADDFKGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARIG DSSPSDYWGQ GTLVTVSSAS
            TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
            YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS
            VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST
            YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT
            KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
            GNVFSCSVMH EALHNHYTQK SLSLSPG
            (Light chain)
            EIVMTQSPAT LSVSPGERAT LSCKASQSVS NDVVWYQQKP GQAPRLLIYY ASNRYTGIPA
            RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ DYTSPWTFGQ GTKLEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H145-H201, H221-L214, H227-H'227, H230-H'230, H262-H322, H368-H426, H'22-H'96, H'145-H'201, H'221-L'214, H'262-H'322, H'368-H'426, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  TYPE      Peptide
EFFICACY    Antineoplastic, Anti-DLL3 antibody
  TYPE      Monoclonal antibody
TARGET      DLL3 [HSA:10683] [KO:K06051]
  PATHWAY   hsa04330(10683)  Notch signaling pathway
            hsa04658(10683)  Th1 and Th2 cell differentiation
            hsa05200(10683)  Pathways in cancer
BRITE       Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Signaling molecules
               Notch signaling
                DLL3
                 D11117  Rovalpituzumab (USAN)
DBLINKS     CAS: 1613313-01-1
            PubChem: 376219041
///
